Continued progress across pipeline programs with focus on pancreatic cancer

Mid-year report of Ampligen ® (rintatolimod) in combination with AstraZeneca’s Imfinzi ® (durvalumab) for the treatment of pancreatic cancer demonstrates promising signs of both no significant toxicity and superior PFS and OS

Bolstered cash position provides runway to fund operations for approximately 12 months

OCALA, Fla., Aug. 15, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today reported its financial results for the second quarter 2025.

“Through the second quarter, we continued to prioritize and accelerate our development efforts for Ampligen, particularly in our Phase 2 trial for locally advanced pancreatic cancer in collaboration with Erasmus Medical Center and AstraZeneca. We remain encouraged by the growing body of positive clinical data demonstrated to date and believe that as we build momentum, we are well positioned to execute on a clear path toward government approval. Pancreatic cancer is one of the most aggressive and difficult-to-treat cancers, and our mission remains focused on making a meaningful difference in this space for patients,” commented AIM Chief Executive Officer Thomas K. Equels.

Recent Highlights

  • Resumed trading on the NYSE American;
  • Closed public equity offering in July, raising $8.0 million in gross proceeds, which is expected to fund operations for approximately 12 months;
  • Reported positive data in a mid-year update from the ongoing Phase 2 DURIPANC clinical study evaluating Ampligen in combination with AstraZeneca’s anti-PD-L1 immune checkpoint inhibitor Imfinzi (durvalumab) in the treatment of metastatic pancreatic cancer patients with stable disease post-FOLFIRINOX (See: NCT05927142 );
  • Announced upcoming presentations at the International 5 th Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care;
  • Ampligen oncology data was presented at scientific congresses including the Annual Meeting of the American Association of Immunologists and U.S.-Poland Science and Technology Symposium 2025.

For more information, please visit the Company’s website at aimimmuno.com .

Summary of Financial Highlights for Second Quarter 2025

  • As of June 30, 2025, AIM reported cash, cash equivalents and marketable investments of $835,000.
  • Research and development expenses for the three months ended June 30, 2025 were $1.2 million, compared to $1.1 million for the same period in 2024.
  • General and administrative expenses were $1.5 million for the three months ended June 30, 2025, compared to $2.6 million for the same period 2024.
  • The net loss from operations for the three months ended June 30, 2025 was $2.8 million, or $(3.68) per share, compared to $1.8 million, or $(3.00) per share, for the three months ended June 30, 2024.

Please refer to the full 10-Q for complete details.

About AIM ImmunoTech Inc.

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen ® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.

For more information, please visit aimimmuno.com and connect with the Company on X , LinkedIn , and Facebook .

Cautionary Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “continue,” “believe,” “potential,” “upcoming” and other variations thereon and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. Many of these forward-looking statements involve a number of risks and uncertainties. Publication of data, and pre-clinical and clinical success seen to date, does not guarantee that Ampligen will be approved for commercial treatment in any indication. The Company urges investors to consider specifically the various risk factors identified in its most recent Form 10-K, and any risk factors or cautionary statements included in any subsequent Form 10-Q or Form 8-K, filed with the U.S. Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Among other things, for those statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the PSLRA. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof.